Abstract
The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Information, communication, and cancer patients’ trust in the physician: what challenges do we have to face in an era of precision cancer medicine?
Supportive Care in Cancer Open Access 03 September 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Salgado, R. et al. Societal challenges of precision medicine: bringing order to chaos. Eur. J. Cancer 84, 325–334 (2017).
San Miguel, L. & Hulstaert, F. The importance of test accuracy in economic evaluations of companion diagnostics. J. Comp. Eff. Res. 4, 569–577 (2015).
Borrebaeck, C. A. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat. Rev. Cancer 17, 199–204 (2017).
National Institutes of Health. NIH news releases. NIH https://www.nih.gov/news-events/news-releases/nih-partners-11-leading-biopharmaceutical-companies-accelerate-development-new-cancer-immunotherapy-strategies-more-patients, (2017).
Acknowledgements
Medical writing assistance was provided by Jim Heighway PhD, Cancer Communications and Consultancy Ltd, Knutsford, UK and was funded by the EORTC. The IBCD conference was made possible due to the generous support from Amgen (Europe) GmbH; AstraZeneca LP; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristol-Myers Squibb; Celgene International II Sàrl; Région de Bruxelles-Capitale (Innoviris); Janssen Research & Development; LLC, KEOSYS Medical Imaging, Lilly USA, LLC; Pfizer Pharma GmbH; F. Hoffmann-La Roche Ltd; Millennium Pharmaceuticals, Inc. and Transgene SA. Roberto Salgado was supported by the Breast Cancer Research Foundation, New York, USA. (BCRF) (BCRF-16-182).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information box 1
IBCD meeting speakers and affiliations (PDF 59 kb)
Rights and permissions
About this article
Cite this article
Salgado, R., Moore, H., Martens, J. et al. Steps forward for cancer precision medicine. Nat Rev Drug Discov 17, 1–2 (2018). https://doi.org/10.1038/nrd.2017.218
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.218
This article is cited by
-
Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors
Nature Biomedical Engineering (2022)
-
Information, communication, and cancer patients’ trust in the physician: what challenges do we have to face in an era of precision cancer medicine?
Supportive Care in Cancer (2021)
-
Genomanalyse maligner Tumoren
Forum (2019)